LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI) (“Puma” or the “Company”) announced that independent proxy advisory firm Egan-Jones Proxy Services recommends that Puma shareholders revoke all consents on the BLUE Consent Revocation Card, thereby rejecting the consent solicitation by Fredric Eshelman.
